“`html
Brussels – The European Fee accredited on Friday state support price 52 million euros for an funding by the pharmaceutical firm Lek, which belongs to the Swiss group Sandoz, in a high-tech middle for the manufacturing of biosimilar medicines in Lendava. Lek is already constructing the middle within the far northeast of the nation, and the funding was estimated at 400 million {dollars} when it was introduced.
The Lendava manufacturing middle is anticipated to supply 330 new jobs, and together with the biosimilar medicine improvement middle that Sandoz is constructing in Ljubljana, it’s anticipated to extend entry to biosimilar medicines for healthcare methods and sufferers, based on the Slovenian firm.
As reported from Brussels on Friday, Lek’s funding in Lendava will contribute to the EU’s strategic objectives by way of creating new jobs and balanced regional improvement, whereas additionally contributing to the union’s objectives of better drug accessibility. The Fee highlights that the funding may have a constructive influence on employment, improvement, and competitiveness of Pomurje as a much less developed space of Slovenia.
That is at the moment the biggest direct international funding within the nation and the biggest in Lek’s historical past. The brand new middle is anticipated to be operational by the top of 2026. (December 13)
“`
